Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02400476 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
A Phase 2 study, sponsored by Puma Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 563
- Enrollment target
NCT02400476 is a Phase 2 study that has completed, run by Puma Biotechnology. The registered enrollment target is 563 participants.
The verdict
NCT02400476, a Phase 2 study, has completed, sponsored by Puma Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 563 participants
- Enrollment target
Study Summary
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide or other prophylactic measures.
Interventions
- DRUG Neratinib
- DRUG Budesonide
- DRUG Loperamide
- DRUG Colestipol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 563 participants |
| Start Date | 2015-02 |
| Est. Completion | 2021-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02400476
The ClinicalTrials.gov registry entry for NCT02400476 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 563 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Neratinib is the first listed.
NCT02400476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02400476 about?
NCT02400476 is a clinical study titled "An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide". An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide or other prophylactic measures.
What is the current status of trial NCT02400476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 563 participants. The study started on 2015-02. Estimated completion is 2021-04-22.
What interventions are being tested in trial NCT02400476?
The interventions under investigation include: Neratinib (DRUG), Budesonide (DRUG), Loperamide (DRUG), Colestipol (DRUG).
Who is sponsoring clinical trial NCT02400476?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.